The Supreme Court of India has directed the Intellectual Property Appellate Board (IPAB) to hear the Novartis matter on November 3 2008. During the recent patent row involving the cancer drug Glivec (imatinib mesylate) of Swiss pharma major Novartis, the constitution of IPAB came under scrutiny due to its reviews of the Indian patent office's decisions. The Supreme Court ordered the appointment of Dr PC Chakraborty, deputy controller general of patents and designs in the Kolkata office as the new technical member for hearing the Gleevec appeal. This was in response to the concerns expressed by Novartis over the existing member S Chandrasekharan, since he was the patent controller who rejected Novertis' beta patent. The IPAB is the board of appeals for intellectual property matters and consists of a chairman, one judicial member and one technical member.